Genetic Engineering of Dendritic Cells Using Partially Zwitterionic Dendrimer-Entrapped Gold Nanoparticles Boosts Efficient Tumor Immunotherapy
- 2 March 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 23 (3) , 1326-1336
Abstract
Effective processing and cross-priming of tumor neoantigen by dendritic cells (DCs) to T cells for spontaneous immune response generation to effectively kill cancer cells remain challenging in cancer immunotherapy. Here, we report a general approach to genetically engineer DCs through silencing their YTHDF1 protein (an important reader protein responsible for RNA m6A methylation) expression via a dendrimeric non-viral vector to boost effective tumor immunotherapy. Poly(amidoamine) dendrimers of generation 5 were partially decorated with mannose and 1,3-propanesultone and then entrapped with gold (Au) nanoparticles. The created dendrimer nanoplatform has an Au core size of 1.8 nm; possesses desired stability, good cytocompatibility, and excellent YTHDF1 siRNA compression ability; and enables targeted gene silencing of DCs overexpressing mannose receptors to upregulate the expression of CD80 and CD86, markers of DCs maturation, potentially leading to tumor antigen cross-presentation. With these properties owned, the combination of YTHDF1 silencing of DCs with programmed cell death-ligand 1 antibody can boost the best immunotherapy of a xenografted melanoma tumor model through the created antitumor immune responses. Findings in this study demonstrate a general approach of genetic engineering of DCs via a dendrimeric non-viral vector to effectively boost antitumor immunotherapy.Keywords
Funding Information
- Science and Technology Commission of Shanghai Municipality (19XD1400100, 20520710300, 20DZ2254900, 21490711500)
- National Natural Science Foundation of China (21773026, 81761148028)
This publication has 52 references indexed in Scilit:
- Transepithelial transport and toxicity of PAMAM dendrimers: Implications for oral drug deliveryAdvanced Drug Delivery Reviews, 2012
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Cancer immunotherapy comes of ageNature, 2011
- Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectivesChemical Society Reviews, 2011
- Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory FunctionsThe Journal of Immunology, 2011
- Dendritic cells and immunity against cancerJournal of Internal Medicine, 2010
- Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coliClinical and Experimental Immunology, 2009
- Cancer immunotherapy: The past, the present and the futureImmunology & Cell Biology, 2003
- New strategies for enhancing the immunogenicity of tumorsCurrent Opinion in Immunology, 1993
- Starburst Dendrimers: Molecular‐Level Control of Size, Shape, Surface Chemistry, Topology, and Flexibility from Atoms to Macroscopic MatterAngewandte Chemie International Edition, 1990